Nitazoxanide (NTZ) veterinary grade API is handled in seven downstream manufacturing routes—oral tablets, granules/powders, capsules, feed premixes, drinking water concentrates, injectables, and oral suspensions. The process constraint across all routes is aqueous solubility: NTZ is classified as practically insoluble under Ph. Eur. 5.11 when solubility is below 0.1 mg/mL. This classification shifts manufacturing burden toward particle size reduction, wetting, and non-aqueous solubilization. The thiazolide nucleus is susceptible to hydrolysis in alkaline media; therefore pH is maintained below 8.0 unless forced degradation data demonstrate acceptable stability. Downstream manufacturers must also verify regulatory status under 21 CFR 530 for extralabel use and VICH GL49 for residue depletion in food-producing species. Dosage selection is determined by species, body weight, target daily dose, and whether the patient is a companion animal, equine, exotic, or food-producing species.

Tablet Compression of NTZ Operates Within a Dissolution-Limited Window

Direct compression of NTZ is selected only when dose-per-tablet is above 100 mg and the formulation can tolerate a superdisintegrant that draws water into the tablet core. A representative matrix may contain microcrystalline cellulose PH102 (45–55% w/w), croscarmellose sodium (3–5% w/w), sodium starch glycolate (2–4% w/w), colloidal silicon dioxide (0.5–1.0% w/w), and magnesium stearate (0.25–0.5% w/w). Blending is performed in a 500 L V-blender at 15 rpm for 15–20 min; magnesium stearate is added in the final 3 min to limit hydrophobic coating of the API. Compression on a 16-station rotary press with 8 mm flat-faced punches is held between 8 and 14 kN; above 16 kN, capping and lamination increase when NTZ retains an acicular crystal habit and powder moisture is below 2.0% w/w. Tablet hardness is tested by USP <1217> and should remain 6–10 kp; disintegration is tested by USP <701> in purified water at 37 ± 2 °C with a limit of 15 min. Production-scale batches frequently show that over-lubrication above 0.5% w/w magnesium stearate reduces aqueous penetration and delays disintegration beyond the target.

Dissolution is the release-limiting test. USP <711> Apparatus II (paddle) at 50 rpm in 900 mL of 0.1 M HCl with 0.5% w/v sodium lauryl sulfate may be used to maintain sink conditions; acceptance of not less than 75% at 45 min is typical. However, published data for NTZ veterinary tablet dissolution in this exact medium are limited, and the surfactant level should be justified by sink-condition experiments rather than copied from monographs. Content uniformity is evaluated by USP <905> with an acceptance value of not more than 15. Accelerated stability at 40 ± 2 °C and 75 ± 5% RH under VICH GL3 is used to detect tizoxanide formation; if unspecified degradation products exceed 0.2% or total impurities exceed 0.5%, the direct-compression route is rejected in favor of dry granulation or wet granulation.

Why Micronization Precedes Wet Granulation for Low-Solubility Antiprotozoal API

When jet milling reduces NTZ particles to a laser diffraction D90 ≤ 10 µm by ISO 13320:2020, wet granulation becomes necessary because the resulting cohesive powder has an angle of repose above 40° by USP <1174> and a Carr index above 30. Jet milling is performed in a fluidized-bed opposed-jet mill with classifier speed adjusted to 8,000–12,000 rpm. The micronized NTZ is then granulated in a high-shear mixer with impeller speed 300–500 rpm and chopper speed 1500–2500 rpm; a binder solution of povidone K30 (2–5% w/w solids) in purified water is added at 5–10 mL/min per kg of dry powder. Endpoint is controlled by impeller power draw and post-drying moisture content 1.5–3.0% w/w. Drying is performed in a fluid-bed dryer with inlet air at 55–65 °C until loss on drying by USP <731> is not more than 3.0%.

Granule quality is defined by sieve analysis using USP <786> with not less than 70% retained between 125 µm and 250 µm and fines below 75 µm limited to 15%. Bulk density should be 0.45–0.65 g/mL, tapped density 0.55–0.85 g/mL, and compressibility index not more than 28. Aqueous granulation exposes NTZ to heat and moisture, so related substances are measured by Ph. Eur. 2.2.29; if tizoxanide exceeds 0.5% or any unspecified degradant exceeds 0.2%, the wetting time and drying temperature must be reduced or the route replaced by roller compaction. Process-scale batches often show over-wetting at the granulator bowl wall; this failure is detected when impeller torque rises abruptly and produces granules with a bimodal size distribution and subsequent tablet weight variation outside USP <905> limits.

Capsule filling for NTZ is selected when dose titration across body weights from 5 kg to 50 kg is required or when a two-component therapeutic combination must be separated from immediate-release tablet diluents. The milled or slugged powder is blended with colloidal silicon dioxide (0.25–0.5% w/w) and magnesium stearate (0.5% w/w) before encapsulation. On a tamping pin capsule filler, target fill weight variation is not more than ±5% for size 1 or 2 hard gelatin capsules. Fill weight is verified by USP <905> uniformity of dosage units, and disintegration is tested by USP <701> in 0.1 M HCl at 37 ± 2 °C with a 30-min limit. Empty capsule shell compatibility is assessed at 40 ± 2 °C and 75 ± 5% RH over 6 months; gelatin cross-linking occurs if the powder blend moisture exceeds 3.0% w/w or if residual solvents remain above USP <467> Option I limits. Hydroxypropyl methylcellulose capsules reduce cross-linking but may delay dissolution lag time by 3–5 min; that shift must be covered by the dissolution acceptance range. If the flow function coefficient by ASTM D6128-16 ring shear is below 3.0, automatic capsule feed systems require force feeders set at 30–50 rpm.

Feed Premix Manufacturing and the Thermal Boundary Set by Pelleting

Feed premix manufacture begins with carrier selection, not API mixing. Ground corn cob, lactose monohydrate, or rice hulls are dried to moisture below 5.0% w/w by USP <921> Method Ia before use. NTZ powder is geometrically diluted in a 1:3 ratio into a V-blender at 15 rpm for 15–20 min, then transferred to a ribbon mixer at 70% of nominal capacity. Blend uniformity is validated with iron oxide or riboflavin as tracer, requiring a coefficient of variation below 5.0% across 10 sampling points. Final feed concentration is adjusted to the prescription, commonly 10–100 mg/kg NTZ on dry matter. Use in food-producing species is restricted under 21 CFR 530 and requires residue depletion data under VICH GL49; published residue depletion data for NTZ in veterinary feed are limited in some jurisdictions.

Pelleting introduces the critical thermal step. Steam conditioning at 70–85 °C for 30–60 s can produce a die exit temperature above 80 °C; the resulting degradation risk must be quantified by forced thermal studies before pelleting is approved. Published Arrhenius kinetic data for NTZ in feed matrices are limited, so the default manufacturing rule is to hold conditioner temperature below 70 °C or to apply NTZ post-pelleting as a vacuum-coated oil suspension. Pellet durability index should be at least 85% by ASAE S269.5 tumbler method. Cross-contamination is controlled by a validated cleaning procedure; carryover into non-target feed is limited to 1% of the lowest labeled dose unless LC-MS/MS confirms residues below 10 ppb.

Drinking water medication with NTZ requires a hydratable dispersible powder or concentrated solution that remains suspendable in hard water for at least 24 h. The formula typically contains a water-soluble bulking agent such as lactose monohydrate or dextrose (40–60% w/w), a dispersant such as sodium lauryl sulfate (0.1–0.3% w/w), a suspending agent such as xanthan gum (0.1–0.3% w/w), and a chelator such as sodium citrate (0.5–1.0% w/w) to control hardness-related precipitation. High-shear mixing at 2000–3000 rpm for 20–30 min is used to hydrate the polymer network before the API is added. The powder is filled into moisture-proof sachets with desiccant; loss on drying by USP <731> is maintained below 1.5% w/w.

Water dilution is tested in simulated drinking water with total hardness 500 ppm as CaCO₃ and pH 6.0–8.0. Sedimentation after 24 h is assessed by the sedimentation ratio, with a target not less than 0.80. If flocculation occurs, the dispersant concentration is increased, but sodium lauryl sulfate above 0.5% w/w can irritate mucosal surfaces in birds. Assay stability in reconstituted water is tested at 25 °C over 24 h; if assay loss exceeds 5.0%, the product is limited to immediate-use rather than continuous water medication. In poultry, water consumption variability is a production field issue; therefore the final dose must be calibrated to actual water intake per kilogram body weight rather than nominal feed intake.

When Terminal Sterilization Is Not Feasible, Injectable NTZ Manufacturing Shifts to Aseptic Control

When terminal sterilization is not feasible, injectable NTZ manufacturing shifts from a thermal validation problem to an aseptic control problem. NTZ is practically insoluble in water, so aqueous vehicles at pH 7.0 provide less than 0.1 mg/mL dissolved drug. Candidate non-aqueous vehicles include polyethylene glycol 400, propylene glycol, DMA, and DMSO; however, published compatibility data for NTZ in these vehicles are limited. A prototype vehicle may combine 30–50% v/v PEG 400 with ethanol 10% v/v and benzyl alcohol 1.5% v/v, adjusted to pH 5.5–6.5. Alkaline pH above 8.0 is an incompatibility because the thiazolide ring hydrolyzes to tizoxanide and free amine degradation products.

Steam sterilization at 121 °C for 15 min may be evaluated only after forced degradation studies demonstrate that related substances remain below 0.5% and no single unspecified degradant exceeds 0.2%. Published forced-degradation data for NTZ in injection vehicles are limited; therefore aseptic filtration through a 0.22 µm polyvinylidene fluoride membrane is the default route. Filling must occur under EU GMP Annex 1 Grade A conditions. Release tests include sterility by USP <71>, bacterial endotoxins by USP <85> with not more than 2 EU/mg, and particulate matter by USP <788> with not more than 6000 particles ≥ 10 µm and 600 particles ≥ 25 µm per container. Intramuscular injection of PEG-based vehicles above 5 mL per site in cattle or 2 mL per site in dogs may cause muscle irritation and sterile abscess formation; the injection volume must be included in local tolerance studies.

Oral suspension manufacturing is selected for neonatal and small-animal dosing when tablet administration is not feasible. The suspending network is critical because NTZ crystals settle and may cake without controlled rheology. A representative aqueous vehicle may contain xanthan gum (0.2–0.5% w/w), microcrystalline cellulose and carboxymethylcellulose sodium (1.0–2.0% w/w), polysorbate 80 (0.05–0.1% w/w), and sorbitol or sucrose (10–20% w/w) to improve palatability. High-shear mixing at 2000–3000 rpm for 20–30 min is used to hydrate the polymer before adding NTZ. The vehicle is adjusted to pH 5.0–6.0 with citric acid/sodium citrate buffer, and viscosity is measured by Brookfield rotational viscometer spindle 2 at 30 rpm, targeting 200–600 mPa·s.

Sedimentation after 24 h is measured by the sedimentation ratio, with a limit not less than 0.80; resuspendability after 7 days is checked by manual inversion. Dose uniformity by USP <905> is performed on samples shaken for 30 seconds. Photostability is assessed by VICH GL4; if total degradation products exceed 2.0% after 1.2 million lux·h and 200 Wh/m², amber PET packaging is required. Light exposure during compounding must be limited to 500 lux or less. The suspension is filled under ambient temperature; if the batch temperature exceeds 30 °C, viscosity decreases and sedimentation accelerates.